Cereblon – a New Target of Therapy in the Treatment of Multiple Myeloma
| Autor: | David Vrabel, S Sevčíková, Roman Hájek, L Bešše, Lenka Sedlaříková, M Staňková |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
biology
Ubiquitin proteasome Mechanism (biology) Ubiquitin-Protein Ligases Cereblon Gene Expression Pharmacology Cullin Proteins medicine.disease Thalidomide Ubiquitin ligase Oncology Gene expression Biomarkers Tumor biology.protein medicine Humans Multiple Myeloma Receptor Immunosuppressive Agents Multiple myeloma Adaptor Proteins Signal Transducing Peptide Hydrolases medicine.drug |
| Zdroj: | Klinicka onkologie. 27:326-330 |
| ISSN: | 1802-5307 0862-495X |
| Popis: | Treatment of multiple myeloma (MM), currently an incurable disease, aims to achieve complete remission. Immunomodulatory drugs (IMiDs), represented by thalidomide, are one class of very effective drugs. However, the mechanism of IMiDs action is not yet completely understood. Recent research suggests that cereblon (CRBN) plays an important role in mediating anti-tumor effects of IMiDs; therefore, our review focuses on this protein. CRBN is a substrate receptor of Cul4- E3 ubiquitin ligase complex, and thus recognizes proteins destined for degradation. Bind-ing of CRBN and IMiDs inhibits function of the entire ubiquitin proteasome complex which partly explains their anti-tumor effects. In addition, a correlation between CRBN gene expression and effectiveness of treatment in MM patients treated with IMiDs was confirmed. These findings suggest that CRBN expression could possibly serve as a bio-marker to predict response to IMiD in MM patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|